Orexigen, a San Diego based pharmaceutical company, announced on Monday that a new drug designed to help patients overcome obesity had passed three clinical trials and was now one step closer to FDA approval.
Contrave combines buproprion and naltrexone, two drugs used to combat a variety of mental afflictions such as depression and addiction, to reduce food cravings in obese patients. Instead of attempting to create feelings of fullness the drug works to curve the desire to eat simply as a reward or to feel better.